PMC:7309518 / 772-2213 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":369,"end":380},"obj":"Body_part"},{"id":"T5","span":{"begin":462,"end":469},"obj":"Body_part"},{"id":"T6","span":{"begin":507,"end":520},"obj":"Body_part"},{"id":"T7","span":{"begin":525,"end":529},"obj":"Body_part"},{"id":"T8","span":{"begin":638,"end":650},"obj":"Body_part"},{"id":"T9","span":{"begin":655,"end":671},"obj":"Body_part"},{"id":"T10","span":{"begin":672,"end":683},"obj":"Body_part"},{"id":"T11","span":{"begin":825,"end":831},"obj":"Body_part"},{"id":"T12","span":{"begin":951,"end":960},"obj":"Body_part"},{"id":"T13","span":{"begin":1287,"end":1291},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma65239"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma82780"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma79876"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":666,"end":671},"obj":"Body_part"},{"id":"T3","span":{"begin":951,"end":960},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0002298"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":107,"end":110},"obj":"Disease"},{"id":"T19","span":{"begin":112,"end":129},"obj":"Disease"},{"id":"T20","span":{"begin":133,"end":141},"obj":"Disease"},{"id":"T22","span":{"begin":215,"end":223},"obj":"Disease"},{"id":"T23","span":{"begin":225,"end":232},"obj":"Disease"},{"id":"T24","span":{"begin":249,"end":269},"obj":"Disease"},{"id":"T25","span":{"begin":274,"end":289},"obj":"Disease"},{"id":"T26","span":{"begin":345,"end":367},"obj":"Disease"},{"id":"T27","span":{"begin":447,"end":455},"obj":"Disease"},{"id":"T28","span":{"begin":584,"end":594},"obj":"Disease"},{"id":"T29","span":{"begin":621,"end":629},"obj":"Disease"},{"id":"T30","span":{"begin":756,"end":764},"obj":"Disease"},{"id":"T31","span":{"begin":876,"end":884},"obj":"Disease"},{"id":"T32","span":{"begin":895,"end":898},"obj":"Disease"},{"id":"T34","span":{"begin":961,"end":973},"obj":"Disease"},{"id":"T35","span":{"begin":975,"end":995},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0008054"},{"id":"A21","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0021167"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0010528"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0003569"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005851"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005244"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0009722"},{"id":"A33","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0003569"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":525,"end":529},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":655,"end":671},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T5","span":{"begin":825,"end":831},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T6","span":{"begin":825,"end":831},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T7","span":{"begin":825,"end":831},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T8","span":{"begin":825,"end":831},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"},{"id":"T9","span":{"begin":1285,"end":1291},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":369,"end":380},"obj":"Chemical"},{"id":"T4","span":{"begin":400,"end":404},"obj":"Chemical"},{"id":"T5","span":{"begin":462,"end":469},"obj":"Chemical"},{"id":"T6","span":{"begin":484,"end":495},"obj":"Chemical"},{"id":"T7","span":{"begin":491,"end":495},"obj":"Chemical"},{"id":"T8","span":{"begin":507,"end":520},"obj":"Chemical"},{"id":"T9","span":{"begin":545,"end":549},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":650},"obj":"Chemical"},{"id":"T11","span":{"begin":672,"end":683},"obj":"Chemical"},{"id":"T12","span":{"begin":708,"end":716},"obj":"Chemical"},{"id":"T13","span":{"begin":1231,"end":1239},"obj":"Chemical"},{"id":"T14","span":{"begin":1241,"end":1254},"obj":"Chemical"},{"id":"T15","span":{"begin":1256,"end":1268},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_28175"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_26667"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_28175"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_16919"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_62932"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_2948"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PubTator","denotations":[{"id":"49","span":{"begin":708,"end":723},"obj":"Gene"},{"id":"50","span":{"begin":51,"end":58},"obj":"Species"},{"id":"51","span":{"begin":298,"end":303},"obj":"Species"},{"id":"52","span":{"begin":774,"end":782},"obj":"Species"},{"id":"53","span":{"begin":793,"end":801},"obj":"Species"},{"id":"54","span":{"begin":369,"end":380},"obj":"Chemical"},{"id":"55","span":{"begin":484,"end":495},"obj":"Chemical"},{"id":"56","span":{"begin":638,"end":650},"obj":"Chemical"},{"id":"57","span":{"begin":672,"end":683},"obj":"Chemical"},{"id":"58","span":{"begin":1231,"end":1239},"obj":"Chemical"},{"id":"59","span":{"begin":1241,"end":1254},"obj":"Chemical"},{"id":"60","span":{"begin":1256,"end":1268},"obj":"Chemical"},{"id":"61","span":{"begin":78,"end":101},"obj":"Disease"},{"id":"62","span":{"begin":112,"end":129},"obj":"Disease"},{"id":"63","span":{"begin":133,"end":141},"obj":"Disease"},{"id":"64","span":{"begin":215,"end":223},"obj":"Disease"},{"id":"65","span":{"begin":234,"end":241},"obj":"Disease"},{"id":"66","span":{"begin":249,"end":269},"obj":"Disease"},{"id":"67","span":{"begin":274,"end":289},"obj":"Disease"},{"id":"68","span":{"begin":345,"end":367},"obj":"Disease"},{"id":"69","span":{"begin":447,"end":455},"obj":"Disease"},{"id":"70","span":{"begin":577,"end":594},"obj":"Disease"},{"id":"71","span":{"begin":621,"end":629},"obj":"Disease"},{"id":"72","span":{"begin":756,"end":773},"obj":"Disease"},{"id":"73","span":{"begin":817,"end":840},"obj":"Disease"},{"id":"74","span":{"begin":876,"end":884},"obj":"Disease"},{"id":"75","span":{"begin":961,"end":973},"obj":"Disease"},{"id":"76","span":{"begin":975,"end":995},"obj":"Disease"},{"id":"77","span":{"begin":1069,"end":1090},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:51727"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:34205"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:9606"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D005732"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D019158"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D005732"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D006017"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D013256"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D009173"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D001379"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D000208"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D004679"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:D009220"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C000657245"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D000370"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D003389"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D008231"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D019846"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D001039"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D018908"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:C000657245"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D004660"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D003389"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:D003711"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":1341,"end":1356},"obj":"http://purl.obolibrary.org/obo/GO_0045087"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":224},"obj":"Sentence"},{"id":"T12","span":{"begin":225,"end":341},"obj":"Sentence"},{"id":"T13","span":{"begin":342,"end":698},"obj":"Sentence"},{"id":"T14","span":{"begin":699,"end":923},"obj":"Sentence"},{"id":"T15","span":{"begin":924,"end":1164},"obj":"Sentence"},{"id":"T16","span":{"begin":1165,"end":1441},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":400,"end":404},"obj":"GlycoEpitope"},{"id":"T2","span":{"begin":540,"end":549},"obj":"GlycoEpitope"},{"id":"T3","span":{"begin":545,"end":549},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0059"},{"id":"A2","pred":"glyco_epitope_db_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/AN0403"},{"id":"A3","pred":"glyco_epitope_db_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0059"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":133,"end":141},"obj":"Phenotype"},{"id":"T8","span":{"begin":225,"end":232},"obj":"Phenotype"},{"id":"T9","span":{"begin":234,"end":241},"obj":"Phenotype"},{"id":"T10","span":{"begin":274,"end":289},"obj":"Phenotype"},{"id":"T11","span":{"begin":584,"end":594},"obj":"Phenotype"},{"id":"T12","span":{"begin":699,"end":723},"obj":"Phenotype"},{"id":"T13","span":{"begin":825,"end":840},"obj":"Phenotype"},{"id":"T14","span":{"begin":961,"end":973},"obj":"Phenotype"},{"id":"T15","span":{"begin":1001,"end":1027},"obj":"Phenotype"},{"id":"T16","span":{"begin":1069,"end":1082},"obj":"Phenotype"},{"id":"T17","span":{"begin":1151,"end":1163},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0100614"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0000458"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0041051"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0009830"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0003236"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001324"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002383"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0032070"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0011096"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002960"}],"text":"Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (\u003e10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed."}